Sorin invests $8m in Cardiosolutions for transcatheter mitral valve treatment
This article was originally published in Clinica
Executive Summary
Just one week after its last acquisition, Italian cardiovascular firm Sorin has paid $8m for a minority stake in Cardiosolutions, a US company developing a percutaneous system to treat mitral valve regurgitation. The agreement gives Milan-based Sorin the option to acquire Cardiosolutions in the future and underlines the medtech industry's interest in the fast-growting transcatheter heart valve technology space.